Table 1 Baseline characteristics and outcomes of patients with FLT3mut AML treated with FLT3 inhibitor, venetoclax, and 10-day decitabine.

From: Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

 

Newly diagnosed AML (N = 12)

Relapsed/refractory AML (N = 13)

Baseline characteristics

Age, years

70 [69–78]

52 [35–67]

 ≥70 years

6 (50)

2 (15)

Male sex

4 (33)

10 (77)

ECOG performance status ≥2

4 (33)

3 (23)

Peripheral blood blasts, %

9 [3–51]

58 [35–70]

Bone marrow blasts, %

51 [46–75]

64 [54–68]

Diagnosis

De novo

11 (92)

13 (100)

Secondary AML with AHD

1 (8)

0 (0)

ELN 2017 risk group

Favorable

5 (42)

5 (38)

Intermediate

4 (33)

1 (7)

Adverse

3 (25)

7 (54)

ELN 2017 cytogenetic risk

Favorable

0 (0)

0 (0)

Intermediate

12 (100)

9 (69)

Adverse

0 (0)

4 (31)

FLT3

ITD high (≥0.5)

1 (8)

4 (31)

ITD low (<0.5)

7 (58)

6 (46)

TKD

3 (25)

1 (8)

ITD and TKD

1 (8)

1 (8)

Other

0 (0)

1 (8)a

Mutations

 NPM1

6 (50)

7 (54)

 IDH1/2

4 (33)

1 (8)

 TP53

0 (0)

2 (15)

 RUNX1

2 (17)

2 (15)

 ASXL1

3 (25)

1 (8)

 K/NRAS

2 (17)

2 (15)

Prior therapies

0

1 [1–3]

FLT3 inhibitor

 

8 (62)

Hypomethylator (HMA)

 

2 (15)

Intensive chemotherapy (IC)

 

12 (92)

Stem-cell transplantation

 

4 (31)

Outcomes

Composite complete remission rate (CRc)

11 (92)

8 (62)

CR

9 (75)

3 (23)

CRp

2 (17)

0 (0)

CRi

0 (0)

5 (38)

MRD negative

by FCM

5/9 (56)

5/8 (63)

by PCR/NGS

10/11 (91)

7/7 (100)

No response

1 (8)

4 (31)

Aplasia

0 (0)

1 (8)

60-day mortality

0 (0)

1 (8)

Time to response, months

1.5 [1.3–2.7]

1.5 [1.0–2.4]

No. of cycles to response

1 [1–2]

2 [1–2]

  1. All results expressed as no. (%) or median [interquartile range], unless specified. CR = complete remission with <5% blasts and absolute neutrophil count (ANC) ≥ 1 × 109/L and platelet count ≥100 × 109/L, CRp = achievement of all CR criteria except for platelet recovery (platelet count <100 × 109/L), CRi = CR with incomplete hematologic recovery = achievement of all CR criteria except for hematologic recovery with residual neutropenia (ANC < 1 × 109/L) with or without RBC/platelet transfusion independence; aplasia was defined as inevaluable bone marrow sample due to cellularity <10%.
  2. ECOG Eastern Cooperative Oncology Group, AHD antecedent hematological disorder, ELN European LeukemiaNet, MRD minimal residual disease, FCM flow cytometry, PCR polymerase chain reaction, NGS next-generation sequencing.
  3. aOne patient had FLT3 S749L variant.
Back to article page